Skip to main content
ADIM logo

ADIM — Investor Relations & Filings

Ticker · 4142 ISIN · TW0004142005 LEI · 549300M5TV8YGVXU1827 TW Manufacturing
Open in API
Filings indexed 1,804 across all filing types
Latest filing 2020-02-07 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 4142

About ADIM

http://www.adimmune.com.tw/

ADIMMUNE CORPORATION, established in 1965, specializes in the research, development, and large-scale manufacturing of human vaccines and biologics. The company is a primary supplier of seasonal influenza and tetanus vaccines, maintaining production facilities that adhere to PIC/S GMP, US FDA, and EU standards. Its operations encompass the full product lifecycle, from initial R&D to commercial distribution. In addition to its proprietary vaccine portfolio, the company provides Contract Development and Manufacturing Organization (CDMO) services, supporting collaborative development and global supply chains. Recognized for its technical expertise in viral and bacterial vaccine production, the organization focuses on delivering high-quality immunization solutions to international markets while leveraging its history as a pioneering vaccine laboratory.

Recent filings

Filing Released Lang Actions
109年1月營業收入
Interim / Quarterly Report Classification · 95% confidence The document is a monthly revenue summary report for a company named 國光生, showing net operating revenue figures for January 2020 (民國109年01月) with comparisons to the previous year. It includes detailed financial data such as monthly revenue, year-to-date revenue, and percentage changes, along with explanatory notes on revenue changes. The document is short (797 characters) but contains actual financial data and analysis, not just an announcement or a link to a report. It is a periodic financial report for a period shorter than a full fiscal year (monthly data). Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2020-02-07 Chinese
108年12月營業收入
Interim / Quarterly Report Classification · 95% confidence The document is a revenue summary report for a company named 國光生 for the period 民國108年12月 (December 2019). It contains detailed financial data on net operating revenue for the month and year-to-date, with comparisons to the previous year and explanations for changes. The content is concise (808 characters) and focuses on financial figures and explanations, typical of a periodic financial report. It is not an announcement of a report publication, nor a certification or a brief summary. The presence of actual financial data and analysis indicates it is a financial report for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report (IR).
2020-01-09 Chinese
108年12月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a listed company (國光生) reporting on the status of fund loans and endorsement guarantees for the current and previous month, with amounts all zero. It contains no detailed financial statements or analysis, no mention of a fiscal period report, no regulatory certifications, and no announcements about meetings or votes. The content is a regulatory disclosure of financial status but very limited in scope and length (602 characters). It does not fit into detailed report categories like Annual Report (10-K) or Interim Report (IR). It is not a report publication announcement since it contains actual data, albeit minimal. The best fit is Regulatory Filings (RNS), which covers miscellaneous regulatory disclosures that do not fit other categories.
2020-01-09 Chinese
108年12月董事會成員及持股
Director's Dealing Classification · 100% confidence The document is a detailed tabulation of shareholdings by insiders, including directors, supervisors, and major shareholders, with specific numbers of shares held, pledged shares, and related notes. It does not contain financial statements, earnings data, or management discussion. It is a disclosure of insider shareholdings and related information. This type of document corresponds to a Director's Dealing report, which reports personal share transactions or holdings by company directors and executives. The document length is under 5,000 characters and contains detailed insider shareholding data, not a report publication announcement or a general regulatory filing. Therefore, the appropriate classification is Director's Dealing (DIRS).
2020-01-06 Chinese
108年12月內部人持股異動(事後)
Director's Dealing Classification · 100% confidence The document contains detailed tabular data about shareholdings of company insiders, including directors, managers, and their related parties. It lists share counts at different times, increases and decreases in holdings, and types of shares held. This type of information corresponds to disclosures about personal share transactions by company directors and executives, commonly known as insider trading or director dealings. There is no indication of financial statements, earnings data, or meeting materials. The document is not a report or announcement of a report but a direct disclosure of share transactions by insiders.
2020-01-06 Chinese
108年12月變更登記
Share Issue/Capital Change Classification · 95% confidence The document is a brief disclosure from a listed company (國光生) providing details about its capital stock, including authorized capital, paid-in capital, and changes in capital such as convertible bonds converted to shares. The document is short (809 characters) and contains no financial statements or detailed analysis. It is essentially a capital structure update or announcement regarding share capital changes. There is no indication of a full report or detailed financial data. Therefore, it fits best under the category of Share Issue/Capital Change (SHA).
2020-01-03 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.